Tina Kurent

Endoscopic Postoperative Recurrence in Crohn’s Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study

Henit Yanai, A Kagramanova, O. V. Knyazev et al. · Journal of Crohn s and Colitis · 2022 · 59 citations · Full text

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission

Jurij Hanžel, Jurij Zdovc, Tina Kurent et al. · Clinical Gastroenterology and Hepatology · 2020 · 51 citations · Full text

Immunology, Gastroenterology, Biochemical Remission +5

Success and safety of high infliximab trough levels in inflammatory bowel disease

David Drobne, Tina Kurent, Saša Golob et al. · Scandinavian Journal of Gastroenterology · 2018 · 46 citations

Optimised infliximab monotherapy is as effective as optimised combination therapy, but is associated with higher drug consumption in inflammatory bowel disease

David Drobne, Tina Kurent, Saša Golob et al. · Alimentary Pharmacology & Therapeutics · 2019 · 40 citations

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

Jurij Hanžel, Nejc Sever, Ivan Ferkolj et al. · United European Gastroenterology Journal · 2019 · 27 citations · Full text